New Codes for COVID Booster Vaccine & Monoclonal Antibody Products

August 10th, 2021 - Wyn Staheli, Director of Research
0 Votes - Sign in to vote or comment.

As part of ongoing efforts to treat and prevent COVID-19, new vaccines and therapies continue to be added which require new codes for reporting. The following are some changes that have happened recently.

COVID Booster Vaccine Code

On July 30, 2021, the American Medical Association (AMA) announced the addition of a new CPT code (0003A) to report the administration of a third dose of the Pfizer-BioNTech COVID-19 vaccine. Although the FDA granted approval for the first two doses of this vaccine back in December of 2020, according to the AMA website, the code for reporting the third booster dose is effective upon receiving Emergency Use Authorization (EUA) or approval from the FDA. The AMA updated their Appendix Q to reflect this new code.

Monoclonal Antibody Product

Prior to this new booster code, on June 24, 2021, CMS announced new codes (Q0249, M0249, M0250) to report the use of Genentech’s Antibody Tocilizumab for the treatment of COVID-19. Unlike other monoclonal antibodies, which are only authorized to treat a patient with mild-to-moderate COVID-19 who has NOT been hospitalized, Tocilizumab’s EUA is for patients 2 years of age and older who are already hospitalized with severe COVID-19 illness.

Novavax Vaccine Code 

On May 4, 2021, the AMA released new codes to report the Novavax two-dose vaccine; code (91304) and its associated administration codes (0041A, 0042A). These codes will be effective upon receiving emergency use authorization from the FDA. However, Novavax recently stated that they won’t be submitting that request until the fourth quarter of this year even though they plan on requesting an emergency use listing from the World Health Organization (WHO) sometime in August.


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...

Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association